The iLFT platform, presented at the EASL Congress 2024, utilizes an automated algorithm to analyze liver function test results and determine the cause of liver dysfunction in a primary care setting. Real-world data from NHS Tayside in Dundee, Scotland, showed that 68.3% of iLFT tests required further testing, with the most common outcome being metabolic dysfunction-associated steatotic liver disease. The platform identified potential liver fibrosis in 20% of cases and reduced referrals to secondary care by 34% with the inclusion of Enhanced Liver Fibrosis testing. The platform helps primary care practitioners diagnose and manage chronic liver disease more effectively.
Source link
iLFT Platform Helps Detect Chronic Liver Disease
